Ambrx Biopharma, Inc.
AMAMDelisted Mar 7, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001990550
Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Ambrx Biopharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Ambrx Biopharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Maier Paul V | Director | 85,000 | Mar 7, 2024 | 0 |
| Dalesandro Margaret | Director | 70,833 | Mar 7, 2024 | 0 |
| Glover Steve C | Director | 85,000 | Mar 7, 2024 | 0 |
| O'Connor Daniel J. | President and CEO | 0 | Mar 7, 2024 | 0 |
| Nelson Sonja | Chief Financial Officer | 0 | Mar 7, 2024 | 0 |
| Hermans Kate | Director | 85,000 | Mar 7, 2024 | 0 |
| Loesberg Janet | Director | 85,000 | Mar 7, 2024 | 0 |
| Aromando Andrew | Chief Operating Officer | 109,263 | Mar 7, 2024 | 0 |
| Cormorant Asset Management, LP | 10% Owner | 11,231,000Indirect | Oct 25, 2023 | 0 |
| Chen Bihua | 10% Owner | 11,231,000Indirect | Oct 25, 2023 | 0 |
| Cormorant Global Healthcare Master Fund, LP | 10% Owner | 11,231,000Indirect | Oct 25, 2023 | 0 |
| Cormorant Private Healthcare Fund III LP | 10% Owner | 11,231,000Indirect | Oct 25, 2023 | 0 |
| Darwin Global Master Fund, Ltd. | 10% Owner | – | Jun 28, 2023 | 0 |
| Darwin Global Management, Ltd. | 10% Owner | – | Jun 28, 2023 | 0 |
| Trehan Abhishek | 10% Owner | – | Jun 28, 2023 | 0 |
| Chang Xiaowei | Director | – | Jun 9, 2023 | 0 |
| Rupalla Katrin | Director | – | Jan 31, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 8, 2023 (view filing) | Feb 27-Mar 6 | 9 daysLate | Darwin Global Management, Ltd.10% Owner | PPurchase | +26.0M | $0.9253 | +$24.1M | –11.3M after | Derivative3 lots |
| Mar 16, 2023 (view filing)6:04 PM ET | Mar 14-16 | 2 days | Cormorant Asset Management, LP and 3 others10% Owner | PPurchase | +1.00M | $10.21 | +$10.2M | +1.9%53.5M after | 3 lots |
| Apr 17, 2023 (view filing)5:46 PM ET | Apr 13-17 | 4 days | Cormorant Asset Management, LP and 3 others10% Owner | PPurchase | +2.60M | $9.75 | +$25.3M | +4.4%62.1M after | 3 lots |
| Apr 20, 2023 (view filing)6:04 PM ET | Apr 18-20 | 2 days | Cormorant Asset Management, LP and 3 others10% Owner | PPurchase | +5.22M | $11.30 | +$59.0M | +8.4%67.3M after | 3 lots |
| Jun 28, 2023 (view filing)4:45 PM ET | Jun 27 | 1 day | Darwin Global Master Fund, Ltd. and 2 others10% Owner | PPurchase | +37.7M | $1.99 | +$75.0M | –16.7M after | Derivative |
| Sep 19, 2023 (view filing)4:49 PM ET | Sep 15-18 | 4 days | Cormorant Asset Management, LP and 3 others10% Owner | PPurchase | +2.15M | $9.12 | +$19.6M | +3.2%69.5M after | 2 lots |
| Oct 25, 2023 (view filing)4:15 PM ET | Oct 23 | 2 days | Cormorant Asset Management, LP and 3 others10% Owner | PPurchase | +1.31M | $6.99 | +$9.14M | +13.2%11.2M after | |
| Oct 31, 2023 (view filing) | Oct 27 | 4 days | O'Connor Daniel J.President and CEO | SSale | −50.0K | $9.82 | −$491.1K | −12.7%342.8K after | 10b5-1 |
| Oct 31, 2023 (view filing) | Oct 27 | 4 days | Nelson SonjaChief Financial Officer | SSale | −12.8K | $9.82 | −$125.5K | −8.9%130.1K after | 10b5-1 |